| The need for speed: an update on methamphetamine addiction AM Barr, WJ Panenka, GW MacEwan, AE Thornton, DJ Lang, WG Honer, ... Journal of psychiatry and neuroscience 31 (5), 301-313, 2006 | 604 | 2006 |
| Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings WJ Panenka, RM Procyshyn, T Lecomte, GW MacEwan, SW Flynn, ... Drug and alcohol dependence 129 (3), 167-179, 2013 | 503 | 2013 |
| Much of late life cognitive decline is not due to common neurodegenerative pathologies PA Boyle, RS Wilson, L Yu, AM Barr, WG Honer, JA Schneider, ... Annals of neurology 74 (3), 478-489, 2013 | 390 | 2013 |
| Estradiol alleviates depressive-like symptoms in a novel animal model of post-partum depression LAM Galea, JK Wide, AM Barr Behavioural brain research 122 (1), 1-9, 2001 | 363 | 2001 |
| Cognitive deficits in individuals with methamphetamine use disorder: A meta-analysis S Potvin, J Pelletier, S Grot, C Hebert, AM Barr, T Lecomte Addictive behaviors 80, 154-160, 2018 | 320 | 2018 |
| Stimulation of the ventral subiculum of the hippocampus evokes glutamate receptor‐mediated changes in dopamine efflux in the rat nucleus accumbens CD Blaha, CR Yang, SB Floresco, AM Barr, AG Phillips European Journal of Neuroscience 9 (5), 902-911, 1997 | 266 | 1997 |
| Neuroleptic malignant syndrome: a review from a clinically oriented perspective L Tse, A M. Barr, V Scarapicchia, F Vila-Rodriguez Current neuropharmacology 13 (3), 395-406, 2015 | 234 | 2015 |
| Region-specific transcriptional changes following the three antidepressant treatments electro convulsive therapy, sleep deprivation and fluoxetine B Conti, R Maier, AM Barr, MC Morale, X Lu, PP Sanna, G Bilbe, D Hoyer, ... Molecular psychiatry 12 (2), 167-189, 2007 | 234 | 2007 |
| Withdrawal following repeated exposure to d-amphetamine decreases responding for a sucrose solution as measured by a progressive ratio schedule of reinforcement AM Barr, AG Phillips Psychopharmacology 141, 99-106, 1999 | 217 | 1999 |
| A ‘crash’course on psychostimulant withdrawal as a model of depression AM Barr, A Markou, AG Phillips Trends in pharmacological sciences 23 (10), 475-482, 2002 | 199 | 2002 |
| Traumatic brain injury in homeless and marginally housed individuals: a systematic review and meta-analysis JL Stubbs, AE Thornton, JM Sevick, ND Silverberg, AM Barr, WG Honer, ... The Lancet Public Health 5 (1), e19-e32, 2020 | 188 | 2020 |
| Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system JYT Leung, AM Barr, RM Procyshyn, WG Honer, CCY Pang Pharmacology & therapeutics 135 (2), 113-122, 2012 | 182 | 2012 |
| Sex differences in forced-swim and open-field test behaviours after chronic administration of melatonin LA Brotto, AM Barr, BB Gorzalka European journal of pharmacology 402 (1-2), 87-93, 2000 | 169 | 2000 |
| Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients RM Procyshyn, WG Honer, TKY Wu, RWY Ko, SA McIsaac, AH Young, ... The Journal of clinical psychiatry 71 (5), 14124, 2010 | 164 | 2010 |
| A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus X Lu, AM Barr, JW Kinney, P Sanna, B Conti, MM Behrens, T Bartfai Proceedings of the National Academy of Sciences 102 (3), 874-879, 2005 | 164 | 2005 |
| Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests T Bartfai, X Lu, H Badie-Mahdavi, AM Barr, A Mazarati, XY Hua, T Yaksh, ... Proceedings of the National Academy of Sciences 101 (28), 10470-10475, 2004 | 156 | 2004 |
| Hippocampal complexin proteins and cognitive dysfunction in schizophrenia K Sawada, AM Barr, M Nakamura, K Arima, CE Young, AJ Dwork, ... Archives of general psychiatry 62 (3), 263-272, 2005 | 154 | 2005 |
| The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice AM Barr, V Lehmann-Masten, M Paulus, RR Gainetdinov, MG Caron, ... Neuropsychopharmacology 29 (2), 221-228, 2004 | 146 | 2004 |
| Preclinical models of antipsychotic drug-induced metabolic side effects HN Boyda, L Tse, RM Procyshyn, WG Honer, AM Barr Trends in pharmacological sciences 31 (10), 484-497, 2010 | 136 | 2010 |
| Uncoupling protein 2 protects dopaminergic neurons from acute 1, 2, 3, 6‐methyl‐phenyl‐tetrahydropyridine toxicity B Conti, S Sugama, J Lucero, R Winsky‐Sommerer, SA Wirz, P Maher, ... Journal of neurochemistry 93 (2), 493-501, 2005 | 136 | 2005 |
